Sae Won Han

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial

Rui‐Hua Xu, Kei Muro, Satoshi Morita et al. · The Lancet Oncology · 2018 · 160 citations

Medicine, Oncology, Pharmacology +15

Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial

Jin Won Kim, Sae Won Han, Ik-Joo Chung et al. · European Journal of Cancer · 2020 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system

Jeong Mo Bae, Jung Ho Kim, Yoonjin Kwak et al. · British Journal of Cancer · 2017 · 47 citations · Full text

Medicine, Oncology, Pathology +17

Clinical predictors of recurrent venous thromboembolism: A single institute experience in Korea

Tae Min Kim, Jin Soo Kim, Sae Won Han et al. · Thrombosis Research · 2008 · 31 citations

Medicine, Hematology, Surgery +14

Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer

Jee Hyun Kim, Do‐Youn Oh, Yu Jung Kim et al. · Journal of Korean Medical Science · 2005 · 23 citations · Full text

Medicine, Geriatric Medicine, Oncology +17